skip_previous play_arrow skip_next
00:00 00:00
playlist_play chevron_left

Precision Medicine for Heart Failure to Keep Hearts Beating

Featuring: Ayla Annac

In this podcast, we feature entrepreneur Ayla Annac, CEO and President of InvivoSciences Inc. InvivoSciences is a preclinical stage biotech company developing therapeutics for rare types of Heart Failure using a precision medicine approach.

  • cover play_arrow

    Precision Medicine for Heart Failure to Keep Hearts Beating
    Ayla Annac

Precision Medicine for Heart Failure To Keep Hearts Beating

  • Tell us about your business, InvivoSciences and the precision medicine drug discovery technology platform you helped develop
  • What is your philosophy of doing business?
  • What are you developing now for patients with rare type of heart failure with preserved ejection fraction?
  • Who is your ideal industry partners? And how can you help them be more successful with precision medicine platform and Heart failure drug you develop?
  • What do you need to make your dream of keeping all heart beating for patients with heart failure?

You can learn more about Ayla Annac and InvivoSciences online at

Thank you all for listening to this LIGHT UP YOUR BUZZ! podcast brought to you by #AnnieJenningsPR. Visit to learn how you too can enjoy high-powered, NO RETAINER performance publicity to build an influential brand and achieve your marketing and PR goals and objectives.

Tagged as: .


Ayla Annac

Ms. Ayla Annac is an immigrant entrepreneur in biotechnology industry for the last decade who is committed to find a solution to prevent deaths related with heart failure after the loss of her father to heart failure at age 53. Since 2001, she is one of the co-founders of InvivoSciences, Inc. She is also President, CEO, COO, and director of projects at IVS after receiving NIH-Fast Track and Phase IIB funding for "Engineered human tissue based high-throughput compound profiling and drug development". Invivosciences is a pre-clinical-stage biotech company developing therapeutics for rare type of Heart Failure with preserved ejection fraction using a precision medicine approach. We identified IVS201, our oral repurposed drug by deploying our groundbreaking, AI integrated discovery platform and NuHeartTM; patient-derived micro heart tissue technologies. Underlying platform enables us to discover therapeutic targets and drug candidates for other heart failures.

Previous episode
share playlist_add


Sleeping With My Shoes On

Featuring: L.J. Jackson

In this podcast, we feature L.J. Jackson, an Award-Winning Empowerment Expert, Consultant, Leader, and Author of Sleeping with My Shoes On: Reclaim Your Innocence, Reclaim Your Power.  L J. taps into her skills […]

Read more trending_flat

Similar episodes